# ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression

> **NCT06869382** · PHASE4 · COMPLETED · sponsor: **Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation** · enrollment: 26 (actual)

## Conditions studied

- Asthma Patients

## Interventions

- **DRUG:** Foster BDP/Formoterol
- **DRUG:** Omalizimab

## Key facts

- **NCT ID:** NCT06869382
- **Lead sponsor:** Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06869382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06869382, "ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06869382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*